Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration
Merry GF, Munk MR, Dotson RS, Walker MG, Devenyi RG
Acta ophthalmologica · 82 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-12-18 · Acta Ophthalmol · vol. 95 · issue 4 · pp. e270–e277
- Publisher
- Wiley
- Cited
- 113 citations · more than 96% of similar papers · 5.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 33 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Laser Applications in Dentistry and Medicine · Retinal Diseases and Treatments · Ophthalmology and Visual Impairment Studies
- Keywords
- Drusen, Medicine, Macular degeneration, Ophthalmology, Visual acuity, Retinal, Contrast (vision)
- MeSH
- retina, humans, macular degeneration, retinal drusen, tomography, optical coherence, treatment outcome, retrospective studies, follow-up studies, pilot projects, contrast sensitivity, visual acuity, aged, aged, 80 and over, female, male, laser therapy
5 authors
From CA, CH, US
- Graham Merry · correspondingPublic Health Ontario
- Marion Ronit MunkUniversity Hospital of Bern
- Robert S. DotsonPublic Health Ontario
- Michael G. WalkerWalker (United States)
- Robert G. DevenyiUniversity Health Network; University of Toronto; Kensington Health
Abstract
Purpose
To evaluate the efficacy of photobiomodulation (PBM) treatment for patients with dry age-related macular degeneration (AMD).
Methods
Assessments on 42 eyes with dry AMD (age related eye disease study (AREDS) 2-4) were conducted. Multiwavelength light emitting diode (LED) light comprising of yellow (590 nm), red (670 nm) and near-infrared (790 nm) bandwidths was applied to subjects' eyes for a treatment course of 3 weeks. Outcome measures were changes in best-corrected visual acuity (BCVA), contrast sensitivity (CS), drusen volume and central drusen thickness.
Results
Significant improvement in mean BCVA of 5.90 letters (p 3 (p < 0.001) and central drusen thickness was significantly reduced by a mean of 3.78 μm (p < 0.001), while overall central retinal thickness and retinal volume remained stable.
Conclusion
This is the first study demonstrating improvements in functional and anatomical outcomes in dry AMD subjects with PBM therapy. These findings corroborate an earlier pilot study that looked at functional outcome measures. The addition of anatomical evidence contributes to the basis for further development of a non-invasive PBM treatment for dry AMD.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.